The FLAVO Trial: Dietary Flavonoids and Cardiovascular Disease Risk Reduction in Postmenopausal Women With Type 2 Diabetes (FLAVO)

May 12, 2011 updated by: University of East Anglia

Reducing Cardiovascular Risk With Dietary Flavonoids in Post Menopausal Women With Type 2 Diabetes

The purpose of this placebo controlled trial is to determine whether a year long intervention with flavonoids (found in cocoa and soy) is more effective in reducing the risk of cardiovascular disease in postmenopausal women with type 2 diabetes, than standard therapy (statins). A range of markers of cardiovascular disease risk are being studied and volunteers are also providing urine and blood samples. 152 postmenopausal women, from the locality, will be recruited for this study.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

152

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
    • Norfolk
      • Norwich, Norfolk, United Kingdom, NR47TJ
        • University of East Anglia (UK); School of Medicine, Health Policy and Practice

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 70 years (ADULT, OLDER_ADULT, CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria

  • Female
  • Having had a natural menopause and a minimum of 1 year since last menstruation
  • Caucasian
  • under 70 years
  • Type 2 diabetics
  • Those using statins (≥40 mg simvastatin or ≥10 mg atorvastatin) for at least 12 months
  • Not currently taking Hormone Replacement Therapy (HRT) and not having taken HRT for a minimum of 6 months prior to commencement
  • Having no significant past or present medical history of vascular disease, or cancers (specifically breast, uterine or ovarian)
  • Never-smokers, and ex-smokers who have given up smoking at least 12 months before recruitment to the study

Exclusion Criteria

  • Currently taking HRT or having taken this medication within 6 months of the trial
  • Those prescribed to use statin therapy for less than 12 months Significant past or present medical history of vascular disease (including ECG and enzyme confirmed myocardial infarction, clinical angina, ischaemic stroke peripheral vascular disease, intermittent claudication) or cancer (especially breast, uterine or ovarian)
  • Hypertensive's with a systolic BP ≥ 160 mm Hg at maximum, or hypertensive's with a systolic BP ≤160 mm Hg at maximum, but who have received antihypertensive therapy for less than 12 months or have had increases to their medication indicating poor control
  • Current smokers or those having given up smoking less than 12 months before recruitment to the study
  • Those prescribed aspirin for a period of less than 12 months prior to recruitment
  • Those prescribed insulin for a period of less than 12 months prior to recruitment and those having had increases to their medication indicating poor control
  • Regular non-prescribed use of anti-inflammatory pain relief medication (i.e. aspirin, paracetamol, cocodamol).
  • Taking other counter indicative medication e.g. steroidal medication during the trial, or within 1 month of the trial beginning.
  • Taking food / dietary supplements e.g. vitamins, minerals, fish oils, plant oils, isoflavones, soy products, carotenoids during the trial (unless prepared to cease intake during, and 1 month preceding the trial).
  • Having vaccinations (excluding the flu vaccination) or antibiotics within 3 months of start of trial, and those with vaccinations scheduled for during the trial
  • Parallel participation in another research project which involves dietary intervention and/or sampling of biological fluids/material
  • Assessed from the clinical screening: HbA1c ≥ 10%; Creatinine >125µmol/L; ALP > 378 IU/L; ALT >150 IU/L; GGT > 180 IU/L

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Intervention A
Experimental arm enriched with flavonoids
Dietary supplement: Flavonoid enrichment (cocoa / soy compounds)
Flavonoid compounds from cocoa (including epicatechin) and soy to be consumed for 365days in the experimental intervention (versus placebo consumption). 27g chocolate bar the vehicle for flavonoid enrichment.
Other Names:
  • Flavonoid enrichment of compounds found in cocoa and soy versus placebo control
Dietary supplement: Flavonoid enrichment (cocoa / soy compounds)
27g placebo chocolate bar to be consumed for 365 days.
PLACEBO_COMPARATOR: Intervention B
Dietary supplement: Flavonoid enrichment (cocoa / soy compounds)
Flavonoid compounds from cocoa (including epicatechin) and soy to be consumed for 365days in the experimental intervention (versus placebo consumption). 27g chocolate bar the vehicle for flavonoid enrichment.
Other Names:
  • Flavonoid enrichment of compounds found in cocoa and soy versus placebo control
Dietary supplement: Flavonoid enrichment (cocoa / soy compounds)
27g placebo chocolate bar to be consumed for 365 days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in cardiovascular disease risk indictaors - including carotid intima-media thickness (CIMT), total plaque volume (TPV) (at the carotid bifurcation), pulse wave velocity (PWV) and biomarkers of risk in blood samples .
Time Frame: 6 months - 1 year
6 months - 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of East Anglia

Collaborators

Quadram Institute Bioscience
Diabetes UK
Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)
The Bertram Diabetes Centre & Radiology department (Norfolk & Norwich University Hospital, UK)
Frutarom Netherlands B.V. - Soy producer
Barry Callebaut - chocolate manufacturer contracted to produce intervention foods

Investigators

  • Principal Investigator: Aedin MM Cassidy, PhD, University of East Anglia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2008

Primary Completion (ACTUAL)

April 1, 2010

Study Completion (ACTUAL)

April 1, 2010

Study Registration Dates

First Submitted

May 12, 2008

First Submitted That Met QC Criteria

May 12, 2008

First Posted (ESTIMATE)

May 14, 2008

Study Record Updates

Last Update Posted (ESTIMATE)

May 13, 2011

Last Update Submitted That Met QC Criteria

May 12, 2011

Last Verified

May 1, 2011

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • R15098
  • REC Ref: 07/H0310/136

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Disease

Clinical Trials on Flavonoid enrichment (cocoa / soy compounds)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe